Dimensions of hepatocellular carcinoma phenotypic diversity
Authors:
Open Access
- 28 October 2018
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 24 (40) , 4536-4547
Abstract
Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related death worldwide. More than 80% of HCCs arise within chronic liver disease resulting from viral hepatitis, alcohol, hemochromatosis, obesity and metabolic syndrome or genotoxins. Projections based on Western lifestyle and its metabolic consequences anticipate a further increase in incidence, despite recent breakthroughs in the management of viral hepatitis. HCCs display high heterogeneity of molecular phenotypes, which challenges clinical management. However, emerging molecular classifications of HCCs have not yet formed a unified corpus translatable to the clinical practice. Thus, patient management is currently based upon tumor number, size, vascular invasion, performance status and functional liver reserve. Nonetheless, an impressive body of molecular evidence emerged within the last 20 years and is becoming increasingly available to medical practitioners and researchers in the form of repositories. Therefore, the aim this work is to review molecular data underlying HCC classifications and to organize this corpus into the major dimensions explaining HCC phenotypic diversity. Major efforts have been recently made worldwide toward a unifying "clinically-friendly" molecular landscape. As a result, a consensus emerges on three major dimensions explaining the HCC heterogeneity. In the first dimension, tumor cell proliferation and differentiation enabled allocation of HCCs to two major classes presenting profoundly different clinical aggressiveness. In the second dimension, HCC micro-environment and tumor immunity underlie recent the-rapeutic breakthroughs prolonging patients' survival. In the third dimension, metabolic reprogramming, with the recent emergence of subclass-specific metabolic profiles, may lead to adaptive and combined therapeutic approaches. Therefore, here we review recent molecular evidence, their impact on tumor histopathological features and clinical behavior and highlight the remaining challenges to translate our cognitive corpus into patient diagnosis and allocation to therapeutic options.Keywords
This publication has 100 references indexed in Scilit:
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaGenome Research, 2013
- Gene-expression signature of vascular invasion in hepatocellular carcinomaJournal of Hepatology, 2011
- Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular CarcinomaGastroenterology, 2011
- A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma PatientsCancer Research, 2010
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell FeaturesGastroenterology, 2009
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular CarcinomaCancer Research, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinomaBritish Journal of Cancer, 2008
- Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancerHepatology, 2008